GlassScriptPhysician profile
Lisa Patel
NPI 1154810778
$1,522.04
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $606 · 2022: $677 · 2023: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $239.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $238.10 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.30 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.89 | 2021-2022 | |
| Melinta Therapeutics, LLC | $124.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.96 | 2022-2023 | Xifaxan |
| Novo Nordisk INC | $96.67 | 2022-2023 | Rybelsus, Ozempic |
| Vifor Pharma, INC. | $80.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $73.00 | 2022-2023 | |
| Lilly USA, LLC | $55.48 | 2021-2023 | Mounjaro |
| Pfizer INC. | $54.19 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $35.27 | 2022-2023 | Verquvo, Belsomra |
| Renalytix Ai, INC. | $33.58 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Astrazeneca Pharmaceuticals LP | $31.74 | 2022-2023 | Breztri |
| Otsuka America Pharmaceutical, INC. | $27.06 | 2023 | Rexulti |
| Corium, LLC | $24.97 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $23.31 | 2022 | |
| Biogen, INC. | $20.83 | 2021 | |
| Amarin Pharma, INC. | $20.26 | 2021 | |
| Medtronic, INC. | $18.74 | 2022 | |
| Vanda Pharmaceuticals INC. | $18.31 | 2021 | |
| Almatica Pharma LLC | $16.69 | 2022 | |
| Esperion Therapeutics, INC. | $16.09 | 2021 | |
| Amgen INC. | $16.08 | 2022 | |
| Astellas Pharma US INC | $15.46 | 2021 | |
| Abbott Laboratories | $15.31 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.05 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $14.69 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $14.32 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.12 | 2022 | |
| Exact Sciences Corporation | $13.95 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.